scholarly journals Potential Use of Haematopoietic or Mesenchymal Stem Cells in the Treatment of Immune Mediated Neutropenia in Domestic Canines

2021 ◽  
Vol 7 (1) ◽  
pp. 9-10
Author(s):  
Arun HS Kumar
Author(s):  
Kosar Malekpour ◽  
Ali Hazrati ◽  
Marziah Zahar ◽  
Alexander Markov ◽  
Angelina Olegovna Zekiy ◽  
...  

2021 ◽  
Vol 12 (3) ◽  
Author(s):  
Qiuli Liu ◽  
Xiaoyong Chen ◽  
Chang Liu ◽  
Lijie Pan ◽  
Xinmei Kang ◽  
...  

AbstractLiver diseases with different pathogenesis share common pathways of immune-mediated injury. Chitinase-3-like protein 1 (CHI3L1) was induced in both acute and chronic liver injuries, and recent studies reported that it possesses an immunosuppressive ability. CHI3L1 was also expressed in mesenchymal stem cells (MSCs), thus we investigates the role of CHI3L1 in MSC-based therapy for immune-mediated liver injury here. We found that CHI3L1 was highly expressed in human umbilical cord MSCs (hUC-MSCs). Downregulating CHI3L1 mitigated the ability of hUC-MSCs to inhibit T cell activation, proliferation and inflammatory cytokine secretion in vitro. Using Concanavalin A (Con A)-induced liver injury mouse model, we found that silencing CHI3L1 significantly abrogated the hUC-MSCs-mediated alleviation of liver injury, accompanying by weakened suppressive effects on infiltration and activation of hepatic T cells, and secretion of pro-inflammatory cytokines. In addition, recombinant CHI3L1 (rCHI3L1) administration inhibited the proliferation and function of activated T cells, and alleviated the Con A-induced liver injury in mice. Mechanistically, gene set enrichment analysis showed that JAK/STAT signalling pathway was one of the most significantly enriched gene pathways in T cells co-cultured with hUC-MSCs with CHI3L1 knockdown, and further study revealed that CHI3L1 secreted by hUC-MSCs inhibited the STAT1/3 signalling in T cells by upregulating peroxisome proliferator-activated receptor δ (PPARδ). Collectively, our data showed that CHI3L1 was a novel MSC-secreted immunosuppressive factor and provided new insights into therapeutic treatment of immune-mediated liver injury.


Life Sciences ◽  
2019 ◽  
Vol 235 ◽  
pp. 116830 ◽  
Author(s):  
Sahar Rostami Mansoor ◽  
Ebrahim Zabihi ◽  
Maryam Ghasemi-Kasman

Author(s):  
Adam Eljarrah ◽  
Marina Gergues ◽  
Piotr W. Pobiarzyn ◽  
Oleta A. Sandiford ◽  
Pranela Rameshwar

Author(s):  
William Fang ◽  
ZhiTao Sun ◽  
Xiao Chen ◽  
Bo Han ◽  
C. Thomas Vangsness

AbstractMesenchymal stem cells (MSCs) are adult stem cells that have the ability to self-renew and differentiate into several cell lineages including adipocytes, chondrocytes, tenocytes, bones, and myoblasts. These properties make the cell a promising candidate for regenerative medicine applications, especially when dealing with sports injuries in the knee. MSCs can be isolated from almost every type of adult tissue. However, most of the current research focuses on MSCs derived from bone marrow, adipose, and placenta derived products. Synovial fluid-derived MSCs (SF-MSCs) are relatively overlooked but have demonstrated promising therapeutic properties including possessing higher chondrogenic proliferation capabilities than other types of MSCs. Interestingly, SF-MSC population has shown to increase exponentially in patients with joint injury or disease, pointing to a potential use as a biomarker or as a treatment of some orthopaedic disorders. In this review, we go over the current literature on synovial fluid-derived MSCs including the characterization, the animal studies, and discuss future perspectives.


2006 ◽  
Vol 119 ◽  
pp. S66-S67
Author(s):  
Ram Singh ◽  
Brenda Vazquez ◽  
Shweta Dubey ◽  
James Wang

2017 ◽  
Vol Volume 8 ◽  
pp. 33-38 ◽  
Author(s):  
Jaewoo Pak ◽  
Jung Hun Lee ◽  
Kwang Seung Park ◽  
Jeong Ho Jeon ◽  
Sang Hee Lee

Sign in / Sign up

Export Citation Format

Share Document